Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Price Target at $124.27

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $124.2727.

Several research firms have recently commented on DNTH. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Truist Financial boosted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th.

Dianthus Therapeutics Price Performance

NASDAQ:DNTH opened at $111.10 on Wednesday. The firm has a market capitalization of $6.07 billion, a P/E ratio of -26.77 and a beta of 1.22. The business has a 50 day simple moving average of $100.75 and a 200 day simple moving average of $84.99. Dianthus Therapeutics has a 12-month low of $22.76 and a 12-month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Research analysts anticipate that Dianthus Therapeutics will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other news, EVP Ryan Savitz sold 31,249 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president directly owned 30,000 shares of the company’s stock, valued at $2,424,000. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 287,084 shares of company stock valued at $29,615,923. 3.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares during the period. UBS Group AG grew its position in Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after buying an additional 469,547 shares in the last quarter. BNP Paribas Financial Markets grew its position in Dianthus Therapeutics by 1,275.3% in the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after buying an additional 441,156 shares in the last quarter. SummitTX Capital L.P. increased its stake in Dianthus Therapeutics by 13.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after buying an additional 12,118 shares during the period. Finally, California State Teachers Retirement System increased its stake in Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after buying an additional 24,697 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.